Published Research Studies and Abstracts Supported by Cure JM

Research Studies

1. Neutrophil Extracellular Traps in Tissue and Periphery in Juvenile Dermatomyositis

   Bhargavi Duvvuri, Lauren M. Pachman, Gabrielle Morgan, Amer M. Khojah, Marisa Klein-Gitelman, Megan L. Curran, Stephen Doty, and Christian Lood. Arthritis & Rheumatology Vol. 72, No. 2, February 2020,, pp 348-358 DOI 10.1002/art.41078 © 2019, American College of Rheumatology Click Here
   

2. Features Distinguishing Clinically Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM).

   Mamyrova G, Kishi T, Targoff IN, Ehrlich A, Curiel RV, Rider LG and the Childhood Myositis Heterogeneity Collaborative Study Group. Rheumatology (Oxford). 2018 Jul 16. Click Here

3. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry

   Challa, D., Crowson, C.S., Niewold, T.B. Reed, A.M. Clin Rheumatol (2018) 37: 1011. Click Here

4. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

   Lundberg IE, Tjärnlund A, Bottai M The International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland), et al. Annals of the Rheumatic Diseases 2017 Dec 16;76:1955-1964. PMID:29079590. Click Here

5. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects.

   Rider LG*, Ruperto N*, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, Garcia de la Torre I, Reed AM, Song YW, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J**, Aggarwal R**, for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Rheumatology (Oxford). 2017 Nov 1;56(11):1884-1893. PMID: 28977549 PMCID: pending. Click Here

6. Environmental Factors Associated with Disease Flare in Juvenile and Adult Dermatomyositis.

   Mamyrova G, Rider LG, Ehrlich A, Jones O, Pachman LM, Nickeson R, Criscione-Schreiber LG, Jung LK, Miller FW, Katz JD. Rheumatology (Oxford). 2017 Aug 1;56(8):1342-1347. PMID: 28444299, PMCID pending. Click Here

7. The development of a consensus core dataset in Juvenile Dermatomyositis for clinical use to inform research.

   McCann L, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Ann Rheum Dis 2017 October 30. PMID: 29084729. Click Here

8. Decreased CD3-CD16+CD56+ natural killer cell counts in children with orbital myositis: a clue to disease activity.

   Briones MR, Morgan GA, Amoruso MC, Rahmani B, Ryan ME, Pachman LM. RMD Open 2017 Jul 11;3:e000385. doi: 10.1136/rmdopen-2016-000385. PMID: 28955482. Click Here

9. 2016 American College of Rheumatology (ACR) – European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

   Aggarwal R*, Rider LG*, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR , Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW**, Vencovsky J** for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology Collaborative Study Group (PRINTO). Arthritis and Rheumatology, 2017 May;69(5):898-910. PMID: 28382787, PMCID: pending *, ** contributed equally. Click Here

10. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

    Rider LG*, Aggarwal R*, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica R, Knupp de Oliveira S, Lindsley C, Pilkington PA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen A, Dressler F, Saad Magalhães C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J**, Ruperto N** for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO). Arthritis and Rheumatology, 2017 May;69(5):911-923. PMID: 28382778, PMCID: pending *, ** contributed equally. Click Here

11. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

    Aggarwal R*, Rider LG*, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW**, Vencovsky J** for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology Collaborative Study Group (PRINTO). Annals Rheumatic Diseases, 2017 May;76(5):792-801. PMID: 28385805, PMCID pending. *, ** contributed equally. Click Here

12. Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study.

    Xu D, Kachao-Cohana A, Morgan GA, Huang CC, Pachman LM. Pediatr Rheumatol Online J. 1. 2017 May 17;15(1):42. doi: 10.1186/s12969-017-0171-3. PMID: 28514969. Click Here

13. Evaluation of the Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Assessment Tool Binary Method (CAT-BM) in Juvenile Dermatomyositis Among Pediatric Dermatologists, Rheumatologists, and Neurologists.

    Tiao J, Feng R, Berger EM, Brandsema JF, Coughlin CC, Khan N, Kichula EA, Lerman MA, Lvovich S, McMahon PJ, Rider LG, Rubin AI, Scalzi LV, Smith DM, Taxter AJ, Treat JR, Williams RP, Yum SW, Okawa J, Werth VP. Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15596. Epub ahead of print], PMID: 28421601. Click Here

14. Muscle MRI at the time of questionable disease flares in juvenile dermatomyositis (JDM).

    Abdul-Aziz R, Yu CY, Adler B, Bout-Tabaku S, Lintner KE, Moore-Clingenpeel M, Spencer CH. Pediatr Rheumatol Online J. 2017 Apr 12;15(1):25. doi: 10.1186/s12969-017-0154-4. PMID: 28403889. Click Here  

15. Monitoring Change in Volume of Calcifications in Juvenile Myositis: A Pilot Study Using Low Dose Computed Tomography (CT).

    Ibarra M, Rigsby CK, Morga GA, Sammet CL, Huang CC, Xu D, Targoff IN, Pachman LM; Pediatric Rheumatology Online J 2016 Nov 29; 14(1):64; PMID: 27894310. Click Here

16. Gene Copy-Number Variations (CNVs) of Complement C4 and C4A Deficiency in Genetic Risk and Pathogenesis of Juvenile Dermatomyositis.

    Lintner KE, * Patwardhan A, * Rider LG, Abdul-Aziz R, Wu YL, Lunstrom E, Padyukov L, Zhou B, Alhomosh A, Newsom D, White P, Jones KB, O’Hanlon TP, Miller FW, Spencer CH, Yu CY. Ann Rheum Dis. 2016 Sep;75(9):1599-1606. PMID:26493816. Click Here

17. Dense Genotyping of Immune-Related Loci in the Idiopathic Inflammatory Myopathies Confirms HLA alleles as Strongest Genetic Risk Factor and Suggests Different Genetic Background for Major Clinical Subgroups.

    Rothwell S, Cooper RC, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O’Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, Rider LG, Cobb J, Platt H, Molberg O, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O’Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA, and the Myositis Genetics Consortium.Annals of Rheumatic Diseases. Annals of Rheumatic Diseases, 2016 Aug;75(8):1558-66. doi: 10.1136/annrheumdis-2015-208119. Epub 2015 Sep 11. PMID: 26362759, PMCID PMC4757924. Click Here

18. Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

    Habers GE, Huber AM, Mamyrova G, Targoff IN, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG, for the Childhood Myositis Heterogeneity Study Group. Arthritis Rheumatol. 2016 Mar; 68(3): 761–768. PMID: 26474155. PMCID: PMC4767657. NIHMSID: NIHMS730402. Click Here

19. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.

    Lintner KE, Wu YL, Yang Y, Spencer C, Hauptmann G, Hebert LA, Atkinson JP and Yu CY. Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases. Front Immunol. 2016 Feb 15;7:36. doi: 10.3389/fimmu.2016.00036. eCollection 2016. PMID: 26913032. Click Here

20. MiRNA-10a regulation of proinflammatory mediators: An important component in untreated Juvenile Dermatomyositis (JDM).

    Xu D, Huang CC, Kachaochana A, Morgan GA, Bonaldo MF, Soares MB, Sarwark J, Pachman LM. J Rheumatol. 2016 Jan;43(1):161-8. doi: 10.3899/jrheum.141474. Epub 2015 Dec 1. PMID: 26628598.
    Click Here

21. Genome-wide Association Study Identifies HLA 8.1 Ancestral Haplotype Alleles as Major Genetic Risk Factors for Myositis Phenotypes.

    Miller FW, Chen W, O’Hanlon TP, Cooper RG, Vencovsky J, Rider LG, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O’Callaghan A, Radstake T, Isenberg DA, Chinoy H, Ollier WER, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI, with the Myositis Genetics Consortium. Genes and Immunity. Genes Immun. 2015 Oct;16(7):470-80. PMID: 26291516. PMCID: PMC4840953. Click Here

22. Early Illness Features Associated with Mortality in the Juvenile Idiopathic Inflammatory Myopathies.

    Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, and Rider LG, for the Childhood Myositis Heterogeneity Study Group. Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. PMID 24151254. Click Here

23. Pilot Study of Etanercept in Patients with Refractory Juvenile Dermatomyositis

    Rouster-Stevens K, Ferguson L, Morgan G, Huang C-C, Pachman LM. 2014 May;66(5):783-787. PMID 24127327. Click Here

24. Genome-wide Association Study of Dermatomyositis Reveals Genetic Overlap with other Autoimmune Disorders.

    Miller FW, Cooper RG, Ivencovsky J, Rider LG, Danko, K Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O’Callaghan A, Radstake T, Isenberg DA, Chinoy H, Ollier WER, O’Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI, Gregersen PK with the Myositis Genetics Consortium. Arthritis & Rheumatism. 2013 December(12);65:3239-3247. PMID: 23983088. Click Here

25. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy.

    Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Care Res (Hoboken). 2013 Dec;65(12):1969-75. PMID: 23925923. Click Here

26. Lack of Achievement of a Full Score on the Childhood Myositis Assessment Scale (CMAS) by Healthy Four-Year-Olds and Those Recovering From Juvenile Dermatomyositis.

    Quinones R, Morgan GA, Amoruso M, Field R, Pachman LM. Arthritis Care and Research. 2013 Oct;65(10):1697-1701. PMID 23666925. Click Here

27. Detection of Anti-Ro, La, Smith and RNP Autoantibodies by Autoantigen Microarray Analysis and Interferon-Alpha Induction in Juvenile Dermatomyositis.

    Balboni I, Niewold TB, Morgan GA, Limb C, Eloranta M-L, Rönnblom L, Utz PJ, Pachman LM. Arthritis & Rheumatism 2013 Sept, 65 (9) 2424-2429. PMID: 23740815. Click Here

28. Pulmonary Function Tests in Idiopathic Inflammatory Myopathy: Association with Clinical Parameters.

    Prestridge A, Morgan MA, Ferguson L, Huang S, Pachman LM. Arthritis Care and Research,2013 65,Sept (9) 1424-1431. PMID 23568855. Click Here

29. The Myositis Autoantibody Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.

    Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW, for the Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jul. 92:(4):223-243. PMID: 23877355. Click Here

30. Brief report: Ultraviolet Radiation Exposure is Associated With Clinical and Autoantibody Phenotypes in Juvenile Myositis.

    Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis Rheum. 2013 Jul;65(7):1934-41. PMID: 23658122. Click Here

31. The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies.

    Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group. Medicine (Baltimore). 2013 Jan;92(1):25-41. PMID: 23263716. Click Here

32. Increased VCAM-1 (Vascular Cell Adhesion Molecule 1) Expression in Short Duration, Untreated Juvenile Dermatomyositis Muscle Biopsies is Regulated by miR-126.

    Kim E, Cook-Mills J, Morgan GA, Sredni ST, Pachman LM. Kim E, Cook-Mills J, Morgan GA, Sredni ST, Pachman LM. Arthritis Rheum. 2012 Nov;64(11):3809-17. PMID: 22740338. Click Here

33. Methylation Alterations of WT1 and Homeobox Genes in Inflamed Muscle Biopsies From Untreated Juvenile Dermatomyositis Suggests Self-Renewal Capacity.

    Wang M, Xie H, Shrestha S, Sredni S, Morgan GA, Pachman LM. Arthritis Rheum. 2012 Oct;64(10):3478-85. PMID: 22674142. Click Here

34. Ovarian Teratoma Mimicking Features of Juvenile Dermatomyositis in a Child.

    Ibarra M, Chou P, Pachman LM. Pediatrics. 2011 Nov;128(5):e1293-6. Epub 2011 Oct 3. PMID: 21969283. Click Here

35. Clinical Status and Cardiovascular Risk Profile of Adults With a History of Juvenile Dermatomyositis.

    Eimer M, Brickman W, Seshadri R, Ramsey-Goldman R, McPherson D, Smulevitz B, Stone N, Pachman LM. J Pediatr. 2011 Nov;159(5):795-801. Epub 2011 Jul 23. Jul 22. PMID: 21784434.
    Click Here

36. Double Trouble: Therapeutic Challenges in Patients With Both Juvenile Dermatomyositis and Psoriasis.

    Kim NN, Lio PA, Morgan GA, Jarvis J, Pachman LM. Arch Dermatol. 2011 Jul;147(7):831-5. Epub 2011 Mar 21. PMID: 21422326. Click Here

37. Parents’ Perception of Self-Advocacy of Children with Myositis: an Anonymous Online Survey.

    Katz JD, Mamyrova G, Agarwal S, Jones OY, Bollar H, Huber AM, Rider LG, White PH. Pediatr Rheumatol Online J. 2011 Jun 7;9(1):10. doi: 10.1186/1546-0096-9-10. PMID: 21649897. Click Here

38. Familial Aggregation of Autoimmune Disease in Juvenile Dermatomyositis.

    Niewold T, Wu S, Smith M, Morgan GA, Pachman LM. Pediatrics. 2011 May;127(5):e1239-46. Epub 2011 Apr 18. PMID: 21502224. Click Here

39. Serum Neopterin Levels as a Diagnostic Marker of Hemophagocytic Lymphohistiocytosis Syndrome.

    Ibarra M, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, Pachman LM, O’Gorman MR. Clin Vaccine Immunol. 2011 Apr;18(4):609-14. Epub 2011 Jan 26. PMID: 21270283.
    Click Here

40. Autoantibody to PL-12 (Anti-Alanyl-tRNA synthetase) in an African American Girl With Juvenile Dermatomyositis and Resolution of Interstitial Lung disease.

    Vega P, Ibarra M, Prestridge A, Pachman LM. J Rheumatol. 2011 Feb;38(2):394-5. PMID: 21285181.
    Click Here

41. Environmental Factors Preceding Illness Onset in the Juvenile Idiopathic Inflammatory Myopathies.

    Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW, for the Childhood Myositis Heterogeneity Collaborative Study Group. Rheumatology. 2010 Dec; 49(12):2381-90.Epub 2010 Aug 27. PMID: 20802007. Click Here

42. The Pediatric Rheumatology International Trials Organization Provisional Criteria for the Evaluation of Response to Therapy in Juvenile Dermatomyositis.

    Ruperto N, Pistorio A, Ravelli A, Rider L, Pilkington C, Oliveira S, Wulffraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed A, Wierzbowska M, Feldman B, Harjacek M, Huppertz H, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Gare B, Martini A; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). Arthritis Care Res (Hoboken). 2010 Nov;62(11):1533-41. PMID: 20583105. Click Here

43. Mycophenolate Mofetil: a Possible Therapeutic Agent for Children with Juvenile Dermatomyositis.

    Rouster-Stevens K, Morgan G, Wang D, Pachman LM. Arthritis Care Res (Hoboken). 2010 Oct;62(10): 1446-51. PMID: 20521307. Click Here

44. Gene-Gene-Sex Interaction in Cytokine Gene Polymorphisms Revealed by Serum Interferon Alpha Phenotype in Juvenile Dermatomyositis.

    Niewold TB, Kariuki SN, Morgan, GA, Shrestha S, Pachman LM. J Pediatr. 2010 Oct;157(4):653-57 PMID: 20605164. Click Here

45. Lesional and Nonlesional Skin From Patients With Untreated Juvenile Dermatomyositis Displays Increased Numbers of Mast Cells and Mature Plasmacytoid Dendritic Cells.

    Shrestha S, Wershil B, Sarwark JF, Philipp T, Pachman LM. Arthritis Rheum. 2010 Sept;62(9):2813–22. PMID: 20506305. Click Here

46. Association of Normal Nailfold End Row Loop Numbers With a Shorter Duration of Untreated Disease in Children With Juvenile Dermatomyositis.

    Ostrowski R, Sullivan C, Seshadri R, Morgan GA, Pachman LM. Arthritis Rheum. 2010 May;62(5):1533-8. PMID: 20213809. Click Here

47. Validation of Manual Muscle Testing and a Subset of Eight Muscles for Adult and Juvenile Idiopathic Inflammatory Myopathies.

    Rider L, Koziol D, Giannini E, Jain M, Smith M, Whitney-Mahoney K, Feldman M, Wright S, Lindsley C, Pachman LM, Villalba M, Lovell D, Bowyer S, Plotz P, Miller F, Hicks J. Arthritis Rheum. 2010 Apr;62(4):465-72. PMID: 20391500. Click Here

48. Calcification in a Case of Circumscribed Myositis Ossificans.

    Ibarra M, Chou PM, Pachman LM, Zhao YD, Boskey AL. J Rheumatol. 2010 Apr;37(4):876. PMID: 20360204. Click Here

49. Protocols for the Initial Treatment of Moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference.

    Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, Rider LG, Wallace CA, Feldman BM. Arthritis Care Res (Hoboken). 2010 Feb;62(2):219-25. PMID: 20191521. Click Here

50. Damage Extent and Predictors in Adult and Juvenile Dermatomyositis and Polymyositis Using the Myositis Damage Index.

    Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS). Arthritis and Rheumatism, 2009 Nov; 60(11):3425-3435. PMID: 19877055. Click Here

51. Characterization of Dystrophic Calcification Induced in Mice by Cardiotoxin.

    Zhao Y-D, Urganus A, Spevak L, Shrestha S, Doty SB, Boskey AL, Pachman LM. Calcif Tissue Int. 2009 Sep;85(3):267-75. Epub 2009 Aug 20. PMID: 19690791. Click Here

52. Elevated Serum Interferon-Alpha Activity in Juvenile Dermatomyositis: Associations With Disease Activity at Diagnosis and After Thirty-Six Months of Therapy.

    Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Arthritis Rheum. 2009 Jun;60(6):1815-24. PMID: 19479879. Click Here

53. Juvenile Dermatomyositis (JDM) Calcifications Selectively Displayed Markers of Bone Formation.

    Urganus AL, Zhao Y-D, Pachman LM. Arthritis Rheum. 2009 Apr 15;61(4):501-8. PMID: 19333978.
    Click Here

54. On Determining the Effects of Therapy on Disease Damage in Non-randomized Studies with Multiple Treatments: A study of Juvenile Myositis.

    Lachenbruch PA, Miller FW, Rider LG. Comm. In Statist. – Theory and Methods. 2009 Jan 1, 38: 3268-3281. PMID: 20209035. Click Here

55. Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis.

    Mamyrova G, O’Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GC, Pandey JP, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis and Rheumatism. 2008 Dec; 58: 3941-3950. PMID: 19035492. Click Here

56. Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis.

    Chen Y-W, Shi R, Geraci N, Shrestha S, Gordish-Dressman H, Pachman LM. BMC Immunology, 9:43, 2008 Jul 31. PMID: 18671865. Click Here

57. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis.

    Seshadri R, Feldman B, Ilowite N, Cawkwell GD, Pachman LM. Arthritis Rheum. 2008 Jul 15; 59(7): 989–995. PMID: 18576304. Click Here

58. Juvenile Dermatomyositis and Other Idiopathic Inflammatory Myopathies of Childhood.

    Feldman B, Rider L, Reed A, Pachman LM. Lancet. 2008 Jun 28;371(9631):2201-12. PMID: 18586175. Click Here

59. Autoantibody to Signal Recognition Particle in African American Girls with Juvenile Polymyositis.

    Rouster-Stevens KA, Pachman LM. J Rheumatol 35:927-929, 2008 May. PMID: 18322984. Click Here

60. Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity.

    Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Mercatante Carrick D, Sebring N, O’Hanlon TP, Ruiz Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Study Group. Medicine.2008 Mar; 87: 70- 86. PMID: 18344805. Click Here

61. Pharmacokinetic Study of Oral Prednisolone Compared With Intravenous Methylprednisolone in Patients With Juvenile Dermatomyositis.

    Rouster-Stevens KA, Gursahaney A, Ngai K-L, Daru JA, Pachman LM. Arthritis Rheum (Arthritis Care Res) 59: 222-226, 2008 Feb 15. PMID: 18240180. Click Here

62. Persistent Association of Nailfold Capillaroscopy Changes and Skin Involvement Over Thirty-Six Months With Duration of Untreated Disease in Patients With Juvenile Dermatomyositis.

    Christen-Zaech S; Seshadri R, Sundberg J, Paller AS, Pachman LM. Persistent Association of Nailfold Capillaroscopy Changes and Skin Involvement Over Thirty-Six Months With Duration of Untreated Disease in Patients With Juvenile Dermatomyositis. Arthritis Rheum 58:571-576, 2008 Feb. PMID: 18240225. Click Here

63. Apoptosis in the Skeletal Muscle of Untreated Children with Juvenile Dermatomyositis: Impact of Duration of Untreated Disease.

    Zhao Y-D, Fedczyna TO, McVicker V, Caliendo J, Li H, Pachman LM. Clin Immunol. 125(2):165-172, 2007 Nov. PMID: 17704000. Click Here

64. Late-Onset Gastrointestinal Pain in Juvenile Dermatomyositis as a Manifestation of Ischemic Ulceration from Chronic Endarteropathy.

    Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, Rider LG. Arthritis and Rheumatism (Arthritis Care and Research). 2007 Jun 15; 57: 881 – 884. PMID: 17530691. Click Here

65. RANKL: Osteoprotegerin Ratio and Bone Mineral Density in Children With Untreated Juvenile Dermatomyositis.

    Rouster-Stevens KA, Langman CB, Price HE, Seshadri R, Shore RM, Abbott K, Pachman LM. RANKL: Osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis. Arthritis Rheum. 56(3): 977-983, 2007 Mar. PMID: 17328075. Click Here

66. Immunogenetic Risk and Protective Factors for Juvenile Dermatomyositis in Caucasians.

    Mamyrova G, O’Hanlon TP, Monroe JB, Mercatante Carrick D, Malley JD, Adams S, Reed AM, Shamim EA, James-Newton L, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group. Arthritis and Rheumatism. 2006 Dec; 54: 3979 – 3987. PMID: 17133612. Click Here

67. HLA Polymorphisms in African-Americans With Idiopathic Inflammatory Myopathy: Allelic Profiles Distinguish Patients With Different Clinical Phenotypes and Myositis Autoantibodies.

    O’Hanlon TP, Rider LG, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. Arthritis and Rheum 2006 Nov; 54: 3670-3681. PMID: 17075818. Click Here

68. Composition of Calcifications in Children with Juvenile Dermatomyositis with Chronic Cutaneous Inflammation.

    Pachman LM , Veis A, Stock A, Abbott K, Vicari F, Byrd R, Giczewski D, Webb C, Spevak L, Boskey AL. Arthritis Rheum 54: 3345-3350, 2006 Oct. PMID: 17009308. Click Here

69. MxA gene expression in Juvenile Dermatomyositis Peripheral Blood Mononuclear Cells: Association With Muscle Involvement.

    O’Connor KA, Abbott, KA, Sabin B, Kuroda M, Pachman LM. Clin Immun 120: 125-319-325, 2006 Sep. PMID: 16859997. Click Here

70. Duration of Illness is an Important Variable for Untreated Children with Juvenile Dermatomyositis.

    Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton RL, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray R, Ramsey-Goldman R. J.Pediatr. 148 (2):247-253, 2006 Feb. PMID: 16492437. Click Here

Abstracts

1. Moneta GM, Pires Marafon D, Rosina S, Verardo M, Fiorillo C, Minetti C, Bracci-Laudiero L, Minetti C, Ravelli A, De Benedetti F, Nicolai R. Expression of Both Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features. Abstract (Poster). Global Conference on Myositis (GCOM). Potomac (USA), 2017.
   
2. Moneta GM, Pires Marafon D, Rosina S, Fiorillo C, Verardo M, Bracci-Laudiero L, Minetti C, Ravelli A, De Benedetti F, Nicolai R. Expression of Both Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features. Abstract (Poster). Global Conference on Myositis (GCOM). Paediatric Rheumatology European Society (PReS) Congress (Athens), 2017.
   
3. Nicolai R, Moneta GM, Pires Marafon D, Rosina S, Fiorillo C, Verardo M, Minetti C, BracciLaudiero L, Ravelli A, De Benedetti F. Expression of Both Type I and Type II Interferons Is Increased in Muscle Biopsies of Juvenile Dermatomyositis Patients and Related to Clinical and Histological Features. Abstract (Poster). Abstract (Poster). ACR/ARHP Annual Meeting. San Diego (USA), 2017.
   
4. Nicolai R, Moneta GM, Caiello I, Pires Marafon D, Verardo M, Rosina S, Fiorillo C, BracciLaudiero L, Minetti C, Ravelli A, De Benedetti F. Correlation of Type I Interferon Score and CXCL10 With Cutaneous and Muscular Disease Activity in Juvenile Dermatomyositis Patients. Abstract (Poster). ACR/ARHP Annual Meeting. San Diego (USA), 2017.
   
5. Aleatany Y, Jones OY, Mamyrova G, Rider LG, Curiel RV. Intravenous Immunoglobulin in Combination with Intravenous Methylprednisolone in the Treatment of Calcinosis Associated with Juvenile Dermatomyositis (JDM). (presented at GCOM, May 2017).
   
6. Mamyrova G, Targoff IN, Kishi T, Bayat N, Curiel RV, Miller FW, Rider LG and the Childhood Myositis Heterogenity Collaborative Study Group. Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America. (presented at GCOM, May 2017).
   
7. Mamyrova G, Kishi T, Targoff IN, Curiel RV, Miller FW, Rider LG. Features distinguishing clinically amyopathic juvenile dermatomyositis (CAJDM) from juvenile dermatomyositis (JDM). (abstract accepted for oral presentation at the Japan College of Rheumatology Annual Meeting, Tokyo, April 26-28, 2018).
   
8. Aleatany Y, Jones OY, Mamyrova G, Rider LG, Curiel RV. Intravenous immunoglobulin in combination with intravenous methylprednisolone in the treatment of calcinosis associated with juvenile dermatomyositis (JDM). Abstract presented at the GWU Research Day, April 5, 2017 and at the Rheumatism Society of the District of Columbia 15th Annual Rheumatology Fellows Forum (May 13, 2017).
   
9. Tsaltskan V, Aldous A, Serafi S, Sami H, Mamyrova G, Miller FW, Simmens S, Curiel RV, Jones OY, Rider LG. Clinical Factors Associated with Long-Term Damage and Calcinosis in an Adult-Age Referral Population of Juvenile Myositis Patients. Arthritis Rheumatol. 2017; 69 (suppl 10).
   More Information
   
10. Mamyrova G, Kishi T, Targoff IN, Curiel RV, Miller FW, Rider LG. Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America. Arthritis Rheumatol. 2017; 69 (suppl 10). More Information
    
11. Mamyrova G, Kishi T, Targoff IN, Curiel RV, Miller FW, Rider LG. Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America. Arthritis Rheumatol. 2017; 69 (suppl 4). Presented at the Pediatric Rheumatology Symposium. More Information
    
12. Mamyrova G, Kishi T, Bayat N, Targoff IN, Wu L, Jones OY, Cureil RV, Miller FW, Rider LG. Features Distinguishing Clinically Hypo- and Amyopathic Juvenile Dermatomyositis (CAJDM) from Juvenile Dermatomyositis (JDM). Arthritis Rheumatol. 2016; 68 (suppl 10). More Information
    
13. Ardalan K, Palac HL, Lee J, Wolfe M, Morgan GA, Pachman LM. Longitudinal Predictors of Physical Function in Juvenile Myositis. 2nd Global Conference on Myositis (GCOM) 2017; Potomac, Maryland.
    
14. Roberson E, Cao L, Morales-Heil DJ, Xu D, Galat Y, Galat V, Tarvin S, Huang CC, Pachman LM. Induced Pluripotent Stem Cells from Monozygotic Twins, Discordant for Juvenile Dermatomyositis, Do Not Exhibit Disease-Related MicroRNA or Coding RNA Disease Expression Signatures. 2nd Global Conference on Myositis (GCOM) 2017; Potomac, Maryland.
    
15. Amer Khojah, Megan Curran, Ramsay Fuleihan, Michael Miller, Marisa Klein-Gitelman, Gabrielle Morgan, Spencer Huang, Dong Xu, Lauren Pachman. The Effectiveness of Rituximab in Treatment of Juvenile Dermatomyositis. 2nd Global Conference on Myositis (GCOM) 2017; Potomac, Maryland.
    
16. L. McCann, C. Pilkington, A. Huber, A. Ravelli, D. Appleby, L. Pachman, et al. Development of an Internationally agreed Optimal Dataset for Juvenile Dermatomyositis (JDM) for Clinical & Research use. 2nd Global Conference on Myositis (GCOM) 2017; Potomac, Maryland.
    
17. K. Hoyt, E. Anderson. ML. Curran, RC. Fuhlbrigge, LM Pachman, et al. The Lymphocyte Repertoire in Juvenile Dermatomyositis. 2nd Global Conference on Myositis (GCOM) 2017; Potomac, Maryland.
    
18. Kadakia A, Khojah A, Morgan GA, Curran ML, Benuck I, Huang CC, Xu D, Pachman LM. Dyslipidemia in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4).
    
19. Khojah A, Miller M, Klein-Gitelman M, Curran M, Pachman LM, Fuleihan R. Rituximab-induced hypogammaglobulinemia in Pediatric Patients with Autoimmune Diseases. FOCIS 2017; Chicago, IL.
    
20. Pachman LM, Cao L, Morgan GA, Lubor B, Xu D, Huang CC, Roberson EDO. Retained inflammatory signaling in peripheral blood mononuclear cells from children with quiescent Juvenile Dermatomyositis and active psoriasis Federation of Clinical Immunology Societies (FOCIS) 2017 June 14-17, Chicago, Illinois.
    
21. Xu D, Kachaochana A, Morgan GA, Huang CC, Pachman LM. Endothelial Progenitor Cell Number is not decreased in 34 Children with Juvenile Dermatomyositis. Federation of Clinical Immunology Societies (FOCIS) 2017 June 14-17, Chicago, Illinois.
    
22. Hoyt K, Anderson E, Curran ML, Fuhlbrigge R, Notarangelo LD, Pachman LM, et al. The Lymphocyte Repertoire in Juvenile Dermatomyositis. Federation of Clinical Immunology Societies (FOCIS) 2017 June 14-17, Chicago, Illinois.
    
23. Pachman LM, Curran ML, Morgan GA, Targoff I, Huang H, Xu D, Huang CC. 101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months. Arthritis Rheumatol. 2017; 69 (suppl 10).
    
24. Ardalan K, Palac HL, Lee J, Wolfe M, Morgan GA, Pachman LM. Longitudinal Predictors of Physical Function in Juvenile Myositis. Arthritis Rheumatol. 2017; 69 (suppl 10).
    
25. Ardalan K, Cella D, Pachman LM, Gray EL, Lee J, Fahey K, Wolfe M, Curran ML, Marques MC, Chang RW. Initial Validation of Patient-Reported Outcomes Measurement Information System (PROMIS®) in Children with Juvenile Myositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).
    
26. Huang CC, Hans V, Xu D, Curran ML, Morgan GA, Roberson EDO, Pachman LM. RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).
    
27. Deakin C, Bowes J, Marshall L, Johnson C, Mamyrova G, Curiel R, Rouster-Stevens KA, Schmeling H, Huber A, Feldman BM, Reed AM, Pachman LM, Raychaudhuri S, Eyre S, Wedderburn LR. The Interaction between Genetic Risk Factors and Age of Disease Onset in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).
    
28. Huang CC, Morgan GM, Curran ML , Xu D, Han V , Roberson EDO, Pachman LM. Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody: RNASeq Detection of Gene Dysregulation in PBMCs [abstract] Arthritis Rheumatol 2017; 69 (supplement 10). NB
    
29. Pachman LM, Xu D, Kurudza E, Morgan GA, Korcarz CA, Stein JH, Amoruso M, Huang CC. Documentation of Impaired Endothelial Cell Function by Brachial Artery Reactivity (BAR) in Young Adults with a History of Juvenile Dermatomyositis (JDM): the possible role of miRNA10a Presented NIH “New Directions in Muscle Biology”, 2016 (not published)
    
30. Roberson EDO, Cao L, Morales-Heil DJ, Xu D, Galat Y, Pachman LM, et al. Juvenile Dermatomyositis Patient-Derived Induced Pluripotent Stem Cells Do Not Retain Disease Expression Signatures [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).
    
31. Pachman LM, Curran ML, Morgan GA, Amoruso MC, Targoff IN, and Huang CC. A Five Year Study of 102 Children with Juvenile Myositis: Disease Course and Outcomes. 2016 ACR/ARHP Annual Meeting.
    
32. Xu D, Kachaochana A, Ostrower A, Coon JS, Morgan GA, Zhao H, Huang CC, Bulun SE, Pachman LM. Aromatase gene expression is upregulated in diagnostic muscle biopsies from girls with untreated Juvenile Dermatomyositis. FOCIS 2015, presented as a poster.
    
33. Habers GE, Huber AM, Mamyrova G, O’Hanlon TP, Adams S, Pandey JP, Miller FW, Boonacker C, van Royen-Kerkhof A, Rider LG. A25: the association of immunogenetic and environmental factors with disease course in patients with juvenile idiopathic inflammatory myopathies. Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S39-40. doi: 10.1002/art.38441.
    
34. Rider LG, Aggarwal R, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SF, Lindsley CB, Pilkington CA, Punaro MG, Ravelli A, Reed AM, Rouster-Stevens KA, van Royen-Kerkhof A, Villa L, Rinaldi M, Pistorio A, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J and Ruperto N. A Hybrid Conjoint Analysis Model Is Proposed As the Definition of Minimal, Moderate and Major Clinical Improvement in Juvenile Dermatomyositis Clinical Trials. Arthritis Rheumatol. 2014; 66 (S11): S578.
    
35. Habers GEA, Huber AM, Mamyrova G, Targoff I, Boonacker C, van Brussel M, Miller FW, Rider LG, van Royen-Kerkhof. Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies. Arthritis Rheumatol. 2014; 66 (S11): S579.
    
36. Mamyrova G, Wu L, Huber A, Targoff IN, Miller FW, Rider LG. Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups. Arthritis Rheumatol. 2014; 66 (S11): S579.
    
37. Bussey MR, Morgan GA, Amoruso MC, Rahmani B, Ryan ME, Pachman LM. Decreased CD3- CD16CD56+ natural killer cell counts are associated with disease activity in children with Orbital Myositis. Arthritis Rheum. 2014;66(10):S583.
    
38. Pachman LM, Kachaochana A, Morgan GA, Xu D, Huang CC, Chauhan AK. Increased immune complex levels in children with Juvenile Dermatomyositis are not associated with levels of von willebrand factor antigen, C4, duration of illness, disease activity score, or the absolute NK count. Arthritis Rheum. 2014;66(10):S968.
    
39. G Mamyrova, LG Rider, O Jones, A Ehrlich, LM Pachman, R Nickeson, LG Criscione-Schreiber, FW Miller, LK Jung and JD Katz. Environmental Factors Associated With Disease Flare In Juvenile and Adult Dermatomyositis. Arthritis and Rheumatism 2013. 65 (suppl). S888.
    
40. Pachman LM, Morgan GA,Huskin A, Malaisrie SC, Spevak L, Doty S, Boskey A. Structure of calcifications In Juvenile Dermatomyositis differs from calcified aortic valves removed from adults without JDM. Arthritis Rheum 2013;93 Suppl 10:228.
    
41. Pachman LM, McMahon MA, Polonsky T, Morgan GA, Amoruso M, Huang C. A pilot study of young adults with Juvenile Dermatomyositis with decreased nailfold capillary end row loops: brachial artery reactivity and oxidized lipids. Arthritis Rheum. 2013;539(10):1277.
    
42. Morgan, GA et al Dermatomyositis. Utility and reliability of digital nailfold capillaroscopy in children with Juvenile Dermatomyositis: three methods. Arthritis and Rheum. 2013;888(10):2083.
    
43. Xu D, Kachaochana A, Morgan GA, Huang C, Pachman LM. Downregulation of mir-10a is associated with increased von willebrand factor antigen, disease activity score and earlier diagnosis in children with untreated Juvenile Dermatomyositis. Arthritic and Rheum 2013: 890 Suppl 10:2089.
    
44. AM Huber, G Mamyrova, J Lee, PA. Lachenbruch, IN. Targoff, FW. Miller and LG. Rider for the Childhood Myositis Heterogeneity Study Group. Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatism, 2012. 64 (suppl). S127-128.
    
45. Pachman LM, Lintner KE, Wu YL, Ferguson LJ, Morgan GA, Huang CC, Yu CY. Decreased C4A Gene Copy Numbers in Children with Juvenile Dermatomyositis: Association with Decreased C4 Protein and Lower Absolute Number of CD3 Negative CD16/56+ Natural Killer Cells. Arthritis Rheum 2012; 64 Suppl 10:1948.;
    
46. Pachman LM, Morgan GA, Curran ML, Ferguson LJ, Huang CC. Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 10-Year Study. Arthritis Rheum 2012;64 Suppl 10:301.
    
47. Xu D, Kachaochana A, Morgan GA, Vanin EF, Soares MB, Pachman LM. Microarray Analysis for microRNA Expression in Juvenile Dermatomyositis (JDM). Arthritis Rheum 2012;64 Suppl 10:1670.
    
48. G. Mamyrova, JD. Katz, RV. Jones, P. Lachenbruch, M. Shah, OY. Jones, A Chahal, S Agrawal, FW. Miller, LG. Rider. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children. Arthritis and Rheumatism, 2012. 64 (suppl). S123.
    
49. Xu D, Kachaochana A, Morgan GA, Vanin EF, Soares MB, Pachman LM. Microarray analysis for microRNA Expression in Juvenile Dermatomyositis (JDM). Arthritis Rheum 2012;64 Suppl 10:1670.
    
50. Pachman LM, Lintner KE, Wu YL, Ferguson LJ, Morgan GA, Huang CC, Yu CY. Decreased C4A gene copy numbers in children with Juvenile Dermatomyositis: Association with decreased C4 protein and lower absolute number of CD3 negative CD16/56+ natural killer cells. Arthritis Rheum 2012;64 Suppl 10:1948.
    
51. Pachman LM, Morgan GA, Curran ML, Ferguson LJ, Huang CC. Decreased frequency of dystrophic calcifications in children with Juvenile Dermatomyositis: A 10-Year Study. Arthritis Rheum 2012;64 Suppl 10:301.
    
52. FW Miller, RG Cooper, J Vencovsky, LG Rider, K Danko, LR Wedderburn, IE Lundberg, LM Pachman, AM Reed, SR Ytterberg, L Padyukov, A Selva O’Callaghan, TR Radstake, DA Isenberg, H Chinoy, W Ollier, TP O’Hanlon, B Peng, P Scheet, A Lee, JA Lamb, WV Chen, CI Amos, and PK Gregersen, with the Myositis Genetics Consortium. Genome-wide Association Study of Dermatomyositis Reveals Shared Genetic Risk Factors with Other Autoimmune Diseases. Arthritis and Rheumatism, 2011,63: S656.
    
53. Sredni S, Hendrickson P, Morgan GA, Shrestha S, Huang CC, Chen YW, Pachman LM. Pathophysiology of untreated Juvenile Dermatomyositis muscle: Hypoxia and apoptosis are regulated by microRNAs. Clinical Immunology Society Annual Meeting, Chicago, 2011.
    
54. Kim E, Cook-Mills J, Caliendo J, Morgan GA, Pachman LM. Short duration of untreated disease is associated with increased VCAM-1 expression in Juvenile Dermatomyositis diagnostic muscle biopsies. Clinical Immunology Society Annual Meeting, Chicago, May 2011.
    
55. Kim E, Cook-Mills J, Morgan GA, Caliendo J, Sredni ST, Pachman LM. miRNA-126 regulates increased VCAM-1 expression in muscle biopsies from children with untreated Juvenile Dermatomyositis of short disease duration. Arthritis Rheum 2011;63 Suppl 10:32.
    
56. Prestridge A, Morgan GA, Wang D, Pachman LM. Pulmonary function tests in idiopathic inflammatory myopathy: association with clinical parameters. Arthritis Rheum 2011;63 Suppl 10:248
    
57. Wang M, Xie H, Hendrickson P, Shrestha S, Sredni ST, Morgan GA, Pachman LM. Epigenetic control of muscle repair identified in diagnostic muscle biopsies from untreated children with Juvenile Dermatomyositis. Arthritis Rheum 2011;63 Suppl 10:252.
    
58. Sredni ST, Hendrickson P, Kim E, Morgan GA, Shrestha S, Chen Y, Huang C, Pachman LM. microRNAs miR-15b and miR-206 are key factors in the regulation of impaired angiogenesis in muscle of children with untreated Juvenile Dermatomyositis. Arthritis Rheum 2011;63 Suppl 10:819.
    
59. Shrestha S, O’Gorman M, Orange J, Tessler-Verville C, Snow K, Morgan GA, Wang D, Pachman LM. Natural killer cells in untreated Juvenile Dermatomyositis: Altered peripheral blood receptors and increased localization in inflamed muscle. Arthritis Rheum 2011;63 Suppl 10:992.
    
60. Miller F, Cooper R, Vencovsky J, Rider LG, Danko K, Wedderburn L, Lundberg I, Pachman LM, et al. Genome-wide association study of Dermatomyositis reveals shared genetic risk factors with other autoimmune diseases. Arthritis Rheum 2011;63 Suppl 10:1678.
    
61. Quinones R, Morgan GA, Amoruso M, Wang D, Pachman LM. The Childhood Myositis Assessment Scale (CMAS) total score in healthy children, age 4-5 years, is 46, not 52. Arthritis Rheum 2011;63 Suppl 10:2011.
    
62. L. Rider, L. Wu, Gulnara. Mamyrova, D. Sherry, M. Perez, C. Wallace, L. Imundo, CA Bingham, L. Zemel, C. Lindsley, R. Rivas-Chacon, P. White, R. Rennebohm, M. Henrickson, I. Targoff, F. Miller and Childhood Myositis Heterogeneity Study Group. Environmental Factors Preceding Illness Onset Differ in Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatism, 2010. 62S: S699-700.
    
63. Ibarra M, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan GA, Pachman LM, O’Gorman MRG. Serum neopterin levels as a diagnostic marker of Hemophagocytic Lymphohistiocytosis Syndrome. Clin Immunol 135, supplement, T39, 2010.
    
64. Niewold TB, Wu S, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in families of children with Juvenile Dermatomyositis: Family history of Lupus is associated with increased IFN-α. Clin Immunol 135, supplement, S23, 2010.
    
65. Ibarra M, Rigsby C, Morgan GA, Wang D, Pachman LM. Measuring Changes in calcifications in Juvenile Dermatomyositis (JDM) using single slice Computerized Tomography (CT). Arthritis Rheum 62(10):S702, 2010.
    
66. Pachman LM, Wang M, Xie H, Hendrickson P, Shrestha S, Morgan GA. Epigenetic studies characteristic of muscle biopsies (MBx) from untreated children with Juvenile Myositis (JM). Arthritis Rheum 62(10):S345, 2010.
    
67. Pachman LM, Chen Y-W, Hendrickson P, Shrestha S, Morgan GA, Sredni S. Pilot study of gene expression profile differences in Juvenile Dermatomyositis (JDM) responders and non-responders: Diagnostic and follow-up muscle biopsy data. Arthritis Rheum 62(10):S102, 2010.
    
68. Sredni S, Hendrickson P, Shrestha S, Pachman LM. MicroRNA expression in Juvenile Dermatomyositis (JDM): clues to disease pathogenesis and chronicity. Arthritis Rheum 62(10):S384, 2010.
    
69. Niewold T, Kariuki S, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon alpha activity in Juvenile Dermatomyositis: Associates with disease activity at diagnosis and after 36 months of therapy. Clin Immunol 131, supplement, S109, 2009.
    
70. Balboni I, Niewold T, Morgan GA, Limb C, Eloranta ML, Utz P, Rönnbolm L, Pachman LM. Concordance of serologic data in Juvenile Dermatomyositis: Interferon-alpha induction and activity, and detectable levels of anti-ro and anti-la autoantibodies. Clin Immunol 131, supplement, S134, 2009.
    
71. Pachman LM, Niewold T, Shrestha S, Morgan GA, Sullivan C. TNF-α Levels and IFN-α activity in children with Juvenile Dermatomyositis (JDM) are associated and modified by etanercept. Clin Immunol 131, supplement, S158, 2009.
    
72. Shrestha S, Wershil B, Sarwark JF, Pachman LM. Increased mast cells in untreated JDM skin compared to paired JDM muscle: Association with mature plasmacytoid dendritic cells. Arthritis Rheum 60(10):S305, 2009.
    
73. Geraci N, Pachman LM, Morgan GA, Chen Y-W. Juvenile Dermatomyositis (JDM): Responders and non-responders to medical therapy have differential genetic profiles. Arthritis Rheum 60(10):S496, 2009.2
    
74. Niewold T, Wu S, Smith M, Morgan GA, Pachman LM. Familial aggregation of autoimmune disease in families of children with Juvenile Dermatomyositis: Family history of Lupus is associated with increased INF-α. Arthritis Rheum 60(10):S496, 2009.
    
75. Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan GA, Pachman LM, O’Gorman MRG. Evaluation of serum neopterin level as a diagnostic marker of Hemaphagocytic Lymphohistiocytosis syndrome (HLH). Arthritis Rheum 60(10):S496, 2009.
    
76. Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Genetic regulation of serum IFN-α in Juvenile Dermatomyositis. Arthritis Rheum 60(10):S497, 2009.
    
77. L. Rider, P. Lachenbruch, L. James-Newton, I. Cabalar, B.M. Feldman, A. Ravelli, B. Myones, R. Rennebohm, L. Pachman, M. Villalba, E. Adams, C. Lindsley, C. Wallace, S. Ballinger, L. Zemel, A. Reed, F. Miller, IMACS Group Effects of Treatment on Disease Damage in Juvenile and Adult Myositis . Arthritris and Rheumatism, 2008; 58S, S229.
    
78. Ibarra M, Zhao Y-D, Boskey AL, Chou PM, Pachman LM. Characterization of calcification in circumscribed myositis ossificans by Fourier Transform Infrared Spectroscopic Imaging (FTIRI). Keystone meeting, Ped Rheumatology, 2008.
    
79. Pachman LM, Shrestra S, Geraci N, Morgan GA, Chen Y-W. Duration of untreated Juvenile Dermatomyositis (JDM) at diagnosis: Impact on muscle biopsy (MBx) gene expression profiles, comparisons with polymyositis (PM). NIH muscle physiology meeting, New Orleans, 2008.
    
80. Pachman LM, Geraci N, Morgan GA, Daniels B, Seshadri R, Sullivan D, O’Gorman MRG. Absolute number of circulating CD3-CD56+/CD16+ natural killer (NK) cells, a potential biomarker of disease activity in Juvenile Dermatomyositis (JDM). Arthritis Rheum 58(9):S225, 2008.
    
81. Niewold TB, Kariuki SN, Morgan GA, Geraci N, Shrestha S, Pachman LM. Serum interferon alpha activity is associated with biological markers of disease activity and severity in Juvenile Dermatomyositis. Arthritis Rheum 58(9):S501, 2008.
    
82. Scalici J, Zhao YD, Morgan GA, Sullivan C, Seshadri R, Pachman LM. Descriptive analysis of the clinical features of patients with Juvenile Dermatomyositis and Partial Lipodystrophy. Arthritis Rheum 58(9):S231, 2008.
    
83. Ostrowski RA, Sullivan CL, Seshadri R, Morgan GA, Pachman LM. Normal nailfold end row loops are associated with a shorter duration of untreated disease in children with Juvenile Dermatomyositis. Arthritis Rheum 58(9):S255, 2008.
    
84. Pachman LM, Neiwold TB, Kariuki SN, Morgan GA, Geraci N, Chen Y-W. Decreased type-1 Interferon in sera of untreated children with Juvenile Polymyositis (JPM) compared with Juvenile Dermatomyositis (JDM) matched for short disease duration. Arthritis Rheum 58(9):S225, 2008.
    
85. Urganus AL, Zhao Y, Pachman LM. Calcifications in Children with Juvenile Dermatomyositis (JDM) contain several bone formation markers. JBMR 154, 23S1, 2008.
    
86. G. Mamyrova, CA. Bingham, EA Oral, K. Rother, E. Cochran, N. Sebring, J. Pandey, L. James-Newton, T. O’Hanlon, I. Targoff, F. Miller, L. Rider. Clinical and Metabolic Characteristics of Acquired Lipodystrophy in Juvenile Dermatomyositis Arthritis and Rheumatism 2007; 55 (suppl): S145.
    
87. Zhao YD, Urganus A, Chen Y-W, Stern PH , Boskey AL, Pachman LM. Role of cell death and osteogenic activity in injury-induced calcification in TNF-alpha receptor p55-/- p75-/- Mice. JBMR 22, S385, 2007.
    
88. Zhao YD, Spevak L, Urganus A, Tse W, Boskey AL, Pachman LM. Comparison of transgenic mice as an animal model for calcinosis in Juvenile Dermatomyositis (JDM) Arthritis Rheum 56: S 654, 2007.
    
89. Balboni I, Patel P, Limb C, Luera N, Morgan G, Utz P, Pascual V, Pachman LM. Autoantigen microarray analysis of sera from Juvenile Dermatomyositis patients: Association with an SLE-like type I interferon signature. Arthritis Rheum 56:S787, 2007.
    
90. Eimer MJ, Young L, Abbott K, Seshadri R, Gursahaney A , Smulevitz B, Rhew E, Ramsey-Goldman R, McPherson D, Pachman LM. Abnormal cardiovascular risk profile in adult patients with Juvenile Dermatomyositis. Arthritis Rheum 54:S 519, # 1243,2006.
    
91. G. Mamyrova, L. Sillers, T. O’Hanlon, J. Pandey, C. Parks, J. Malley, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, G. S. Cooper, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Interleukin-1 and Tumor Necrosis Factor Alpha Polymorphisms are Risk and Protective Factors for Juvenile Dermatomyositis (JDM). Arthritis and Rheumatism. 2006; 54 (suppl): S831.
    
92. G. Mamyrova, L. Sillers, T. O’Hanlon, J. Pandey, J. Malley, S. Adams, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Cytokine and HLA Alleles Modulate Disease Severity in Juvenile Dermatomyositis (JDM). Arthritis and Rheumatism. 2006; 54 (suppl): S692-693.
    
93. A Bingham, G Mamyrova, E Cochran, E Oral, L James-Newton, A Pokrovnichka, L Imundo, F Miller, L Rider, A Premkumar. MRI Characterization of Regional Fat Loss in Patients with Lipodystrophy Complicating Dermatomyositis. Arthritis and Rheumatism. 2006; 54 (suppl): S169-170.
    
94. Pachman LM, Abbott K, Zhao Y, Veis A, Boskey A. Characterization of pathologic calcification in active juvenile dermatomyositis (JDM). J Immunol 176:S214, abstract # 107.8, 2006.
    
95. Zhao Y-D, Fedczyna TO, Kuroda M, McVicker V, Caliendo J, Abbott K, Li H, Pachman LM. Apopotsis Indices in the skeletal muscle of juvenile dermatomyositis: impact of duration of untreated disease. Arthritis Rheum 54:S657, 2006.
    
96. Rouster-Stevens KA, Seshadri R, Shore RM, Abbott K, Pachman LM. RANKL/OPG is inversely associated with bone mineral density in juvenile dermatomyositis. Arthritis Rheum 54:S681, #1701, 2006.
    
97. Pascual V, Patel P, McVicker V, Abbott K, Gurhsahaney A, Pachman LM. Peripheral blood mononuclear cell gene expression profiles in children with juvenile dermatomyositis/polymyositis (JDM/JPM) share type-1 interferon (IFN) signatures with Systemic Lupus Erythermatosus (SLE) but are distinct. Arthritis Rheum 54:S695, # 1743, 2006.
    
98. Rouster-Stevens KA, Pachman LM. Mycophenolate mofetil in Juvenile Dermatomyositis. Arthritis Rheum 54:S680, # 1700, 2006.
    
99. Eimer MJ, Young L, Abbott K, Seshadri R, Gursahaney A , Smulevitz B, Rhew E, Ramsey-Goldman R, McPherson D, Pachman LM. Abnormal cardiovascular risk profile in adult patients with Juvenile Dermatomyositis. Arthritis Rheum 54:S 519, # 1243,2006.
    
100. Pascual V, Patel P, McVicker V, Abbott K, Gurhsahaney A, Pachman LM. Peripheral blood mononuclear cell gene expression profiles in children with juvenile dermatomyositis/polymyositis (JDM/JPM) share type-1 interferon (IFN) signatures with Systemic Lupus Erythermatosus (SLE) but are distinct. Arthritis Rheum 54:S695, # 1743, 2006.
     
101. Rouster-Stevens KA, Pachman LM. Mycophenolate mofetil in Juvenile Dermatomyositis. Arthritis Rheum 54:S680, # 1700, 2006.